Equities

LungLife AI Inc

LungLife AI Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)28.50
  • Today's Change0.00 / 0.00%
  • Shares traded3.75k
  • 1 Year change-49.56%
  • Beta--
Data delayed at least 20 minutes, as of May 01 2024 12:57 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

LungLife AI, Inc. is a developer of clinical diagnostic solutions for lung cancer. The Company is engaged in the development and commercialization of its lung cancer early detection test. Using a minimally invasive blood draw, its LungLB test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. LungLB is a blood-based liquid biopsy assay that uses fluorescence in situ hybridization (FISH) and image analysis to identify circulating genetically abnormal cells (CGAC), which include circulating tumor cells (CTCs). The technique incorporates an artificial intelligence (AI)-derived image analysis strategy to identify unique cell populations reflective of the disease state under interrogation.

  • Revenue in GBP (TTM)36.73k
  • Net income in GBP-4.32m
  • Incorporated2009
  • Employees15.00
  • Location
    LungLife AI Inc2545 W. Hillcrest Drive, Suite 140THOUSAND OAKS 91320United StatesUSA
  • Phone+1 (805) 409-9868
  • Fax+1 (805) 855-2003
  • Websitehttps://www.lunglifeai.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Proteome Sciences plc5.03m-2.44m10.36m35.00------2.06-0.0083-0.00830.017-0.01040.42093.893.04143,657.10-20.45-1.22----32.7654.53-48.59-2.200.2667-2.031.29---35.3710.52-284.38--126.22--
Chill Brands Group PLC146.62k-3.64m11.14m2.00------75.97-0.0142-0.01420.0006-0.00240.03190.09920.363973,310.00-79.21-72.55-141.46-105.3553.05---2,485.30-1,625.460.6499-8.481.17---86.73-50.8923.50---35.95--
Kanabo Group PLC813.00k-4.66m11.70m20.00--0.7693--14.39-0.0108-0.01080.00190.0240.0478.5627.1040,650.00-26.95-75.82-28.68-82.5723.12---572.94-1,786.107.96-13.030.041--726.03---50.96------
Abingdon Health PLC5.34m-2.24m12.17m82.00--6.71--2.28-0.0184-0.01840.04390.01490.89787.674.7465,170.73-37.55-51.31-58.04-79.8557.3533.16-41.82-139.641.59--0.3572--42.68--83.77------
Synairgen plc0.00-9.99m12.57m30.00--0.7871-----0.0496-0.04960.000.07930.00----0.00-41.40-54.75-48.86-60.72-------83,247.62----0.00------63.74--0.00--
Incanthera PLC0.00-1.48m12.91m8.00---------0.0192-0.01920.00-0.00860.00----0.00-373.20-101.74---132.88---------------------36.11------
Genincode PLC1.72m-6.73m13.05m28.00--1.48--7.61-0.0703-0.07030.01790.04970.16816.362.8861,285.71-65.92---72.37--47.55---392.31--5.85--0.0632--23.92---34.21------
Shield Therapeutics PLC7.21m-46.89m13.69m28.00--0.4604--1.90-0.1549-0.15490.01510.0380.16911.800.9805---109.95-42.77-129.39-48.1244.7679.44-650.12-274.352.64-124.940.1756--261.5553.86-151.04---7.68--
Provexis plc598.08k-496.59k14.71m2.00--14.67--24.59-0.0002-0.00020.00030.00040.67173.042.95299,040.00-55.78-48.82-41.86-33.6846.7286.14-83.03-97.641.96--0.00---8.5110.58-71.79------
Destiny Pharma PLC0.00-5.66m17.39m20.00--1.89-----0.0624-0.06240.000.09650.00-------60.33-54.32-67.28-59.97--------------------13.02--35.39--
Oncimmune Holdings PLC1.15m-6.15m17.50m56.00--26.63--15.19-0.08590.05070.01590.00890.12391.080.5941---66.15---131.46--68.75---533.94--3.75-1.960.8897--------------
Verici DX PLC15.17k-8.95m17.54m14.00--2.31--1,155.93-0.0525-0.05250.000090.03140.0013--0.11521,011.31-77.76---92.28--84.21---59,015.79------0.0232-------36.94------
OptiBiotix Health PLC689.10k-13.17m17.87m3.00--1.77--25.94-0.1489-0.14890.00780.10290.04262.281.25229,700.00-81.3517.83-83.4318.6649.3154.87-1,911.88190.543.24-0.0890.00---79.3519.05-58.686.2830.03--
LungLife AI Inc36.73k-4.32m17.89m15.00--1.15--486.98-0.1696-0.16960.00140.24790.0038--0.28312,448.43-44.11---50.09--100.00---11,767.39------0.0419--91.67--28.83------
Skinbiotherapeutics PLC161.65k-2.88m18.54m11.00--4.82--114.66-0.0165-0.01650.00090.01920.05220.88710.418114,695.45-93.07-52.07-115.26-57.3362.90---1,784.70-4,694.376.48-379.780.0259--76.65---1.52--18.00--
Hemogenyx Pharmaceuticals PLC0.00-6.69m21.00m17.00--6.53-----0.0061-0.00610.000.00240.00----0.00-101.47-82.19-112.85-95.97-----------28.030.5144-------68.14--36.68--
Data as of May 01 2024. Currency figures normalised to LungLife AI Inc's reporting currency: UK Pound GBX

Institutional shareholders

11.84%Per cent of shares held by top holders
HolderShares% Held
Unicorn Asset Management Ltd.as of 31 Mar 20241.75m6.87%
Lombard Odier Asset Management (Europe) Ltd.as of 22 Mar 20241.27m4.98%
SVM Asset Management Ltd.as of 30 Jun 20230.000.00%
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.